Novo Nordisk lowers cash price for GLP-1 drugs.

In early trading on Tuesday, the stock price of Novo Nordisk fell by 2.1%. Earlier reports said that the company will lower the direct prices of Wegovy and Ozempic to $349 per month in the US as part of an agreement to expand accessibility. Eli Lilly also lowered the pricing of Zepbound. Lilly rose by 0.6% in early trading on Tuesday.